DK1553097T3
(da)
|
1999-02-10 |
2010-12-13 |
Astrazeneca Ab |
Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
|
PE20010306A1
(es)
*
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
EP1990343B1
(en)
|
1999-12-24 |
2012-04-04 |
Aventis Pharma Limited |
Azaindoles
|
DK1268472T3
(da)
|
2000-02-07 |
2004-12-06 |
Bristol Myers Squibb Co |
3-aminopyrazolinhibitorer af cyclinafhængige kinaser
|
EP1264820A4
(en)
*
|
2000-03-14 |
2004-09-15 |
Fujisawa Pharmaceutical Co |
amide compounds
|
ES2236217T3
(es)
|
2000-04-25 |
2005-07-16 |
Bristol-Myers Squibb Company |
Uso de 5.tio.,sulfinil- y sulfonilpirazolo 3,4-b)-piridinas como inhibidores de la quinasa dependiente de la ciclina.
|
WO2002012228A1
(en)
|
2000-08-09 |
2002-02-14 |
Astrazeneca Ab |
Cinnoline compounds
|
MXPA03000252A
(es)
|
2000-08-09 |
2003-06-06 |
Astrazeneca Ab |
Derivados de quinolina que tienen actividad de inhibicion de fcev.
|
AU2001293233A1
(en)
|
2000-09-01 |
2002-03-13 |
Chiron Corporation |
Aza heterocyclic derivatives and their therapeutic use
|
DK1317442T3
(da)
|
2000-09-11 |
2006-02-13 |
Chiron Corp |
Quinolinonderivater som tyrosinkinaseinhibitorer
|
EP1506962B1
(en)
|
2000-10-20 |
2008-07-02 |
Eisai R&D Management Co., Ltd. |
Nitrogen-containing aromatic heterocycles
|
TWI243164B
(en)
|
2001-02-13 |
2005-11-11 |
Aventis Pharma Gmbh |
Acylated indanyl amines and their use as pharmaceuticals
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
US7642278B2
(en)
|
2001-07-03 |
2010-01-05 |
Novartis Vaccines And Diagnostics, Inc. |
Indazole benzimidazole compounds
|
WO2003004488A1
(en)
*
|
2001-07-03 |
2003-01-16 |
Chiron Corporation |
Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
|
US7101884B2
(en)
|
2001-09-14 |
2006-09-05 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US6897208B2
(en)
*
|
2001-10-26 |
2005-05-24 |
Aventis Pharmaceuticals Inc. |
Benzimidazoles
|
FR2831536A1
(fr)
*
|
2001-10-26 |
2003-05-02 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
|
FR2831537B1
(fr)
*
|
2001-10-26 |
2008-02-29 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
|
CA2465247C
(en)
*
|
2001-10-26 |
2010-05-18 |
Aventis Pharmaceuticals Inc. |
Benzimidazoles and analogues and their use as protein kinases inhibitors
|
NZ534171A
(en)
|
2002-02-01 |
2007-06-29 |
Astrazeneca Ab |
Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability
|
US7166293B2
(en)
*
|
2002-03-29 |
2007-01-23 |
Carlsbad Technology, Inc. |
Angiogenesis inhibitors
|
US20050119278A1
(en)
*
|
2002-05-16 |
2005-06-02 |
Che-Ming Teng |
Anti-angiogenesis methods
|
JP2006501217A
(ja)
|
2002-08-12 |
2006-01-12 |
スージェン・インコーポレーテッド |
新規キナーゼ阻害剤としての3−ピロリル−ピリドピラゾールおよび3−ピロリル−インダゾール
|
KR20050037585A
(ko)
|
2002-08-23 |
2005-04-22 |
카이론 코포레이션 |
벤지미다졸 퀴놀리논 및 그들의 사용
|
CA2508319A1
(en)
*
|
2002-12-03 |
2004-06-17 |
Kyowa Hakko Kogyo Co., Ltd. |
Jnk inhibitors
|
EA008501B1
(ru)
*
|
2002-12-19 |
2007-06-29 |
Пфайзер Инк. |
2-(1н-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний
|
US7192976B2
(en)
|
2002-12-21 |
2007-03-20 |
Angion Biomedica Corporation |
Small molecule modulators of hepatocyte growth factor (scatter factor) activity
|
US7521447B2
(en)
|
2003-03-03 |
2009-04-21 |
Array Biopharma Inc. |
P38 inhibitors and methods of use thereof
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
BRPI0409230A
(pt)
*
|
2003-04-03 |
2006-03-28 |
Pfizer |
formas de dosagem compreendendo ag013736
|
EP1618133A1
(en)
*
|
2003-04-17 |
2006-01-25 |
Pfizer Inc. |
Crystal structure of vegfrkd: ligand complexes and methods of use thereof
|
FR2854159B1
(fr)
*
|
2003-04-25 |
2008-01-11 |
Aventis Pharma Sa |
Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
CA2532965C
(en)
|
2003-07-22 |
2013-05-14 |
Astex Therapeutics Limited |
3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
|
WO2005009389A2
(en)
*
|
2003-07-23 |
2005-02-03 |
Exelixis, Inc. |
Anaplastic lymphoma kinase modulators and methods of use
|
AU2004260759B2
(en)
*
|
2003-07-30 |
2010-04-22 |
Kyowa Hakko Kirin Co., Ltd. |
Protein kinase inhibitors
|
EA010165B1
(ru)
*
|
2003-07-30 |
2008-06-30 |
Киова Хакко Когио Ко., Лтд. |
Производные индазола
|
CA2537430A1
(en)
*
|
2003-09-04 |
2005-03-24 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
US20050164300A1
(en)
*
|
2003-09-15 |
2005-07-28 |
Plexxikon, Inc. |
Molecular scaffolds for kinase ligand development
|
US20050182061A1
(en)
*
|
2003-10-02 |
2005-08-18 |
Jeremy Green |
Phthalimide compounds useful as protein kinase inhibitors
|
JP4890255B2
(ja)
|
2003-11-07 |
2012-03-07 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
|
WO2005044788A1
(ja)
|
2003-11-11 |
2005-05-19 |
Eisai Co., Ltd. |
ウレア誘導体およびその製造方法
|
WO2005051942A1
(en)
*
|
2003-11-19 |
2005-06-09 |
Signal Pharmaceuticals, Llc |
Indazole compounds and methods of use thereof as protein kinase inhibitors
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
BRPI0508107A
(pt)
*
|
2004-02-27 |
2007-07-17 |
Hoffmann La Roche |
derivados de indazol e composições farmacêuticas contendo os mesmos
|
JP2007526324A
(ja)
*
|
2004-03-02 |
2007-09-13 |
スミスクライン・ビーチャム・コーポレイション |
Akt活性のある阻害剤
|
JPWO2005094823A1
(ja)
*
|
2004-03-30 |
2007-08-16 |
協和醗酵工業株式会社 |
Flt−3阻害剤
|
WO2005108370A1
(ja)
*
|
2004-04-16 |
2005-11-17 |
Ajinomoto Co., Inc. |
ベンゼン化合物
|
US7585859B2
(en)
|
2004-05-06 |
2009-09-08 |
Plexxikon, Inc. |
PDE4B inhibitors and uses therefor
|
EP1758895A1
(en)
|
2004-06-17 |
2007-03-07 |
Wyeth a Corporation of the State of Delaware |
Gonadotropin releasing hormone receptor antagonists
|
WO2006009736A1
(en)
|
2004-06-17 |
2006-01-26 |
Wyeth |
Processes for preparing gonadotropin releasing hormone receptor antagonists
|
CA2578075A1
(en)
*
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
|
EP1786813A2
(en)
*
|
2004-09-03 |
2007-05-23 |
Plexxikon, Inc. |
Bicyclic heteroaryl pde4b inhibitors
|
KR20070053205A
(ko)
|
2004-09-17 |
2007-05-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
의약 조성물
|
EP1647549A1
(en)
*
|
2004-10-14 |
2006-04-19 |
Laboratoire Theramex |
Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
|
KR20070085727A
(ko)
*
|
2004-11-02 |
2007-08-27 |
화이자 인코포레이티드 |
인다졸 화합물의 제조 방법
|
CA2586177A1
(en)
*
|
2004-11-02 |
2006-05-11 |
Pfizer Inc. |
Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole
|
WO2006048745A1
(en)
*
|
2004-11-02 |
2006-05-11 |
Pfizer Inc. |
Methods for preparing indazole compounds
|
US9512125B2
(en)
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
FR2878442B1
(fr)
*
|
2004-11-29 |
2008-10-24 |
Aventis Pharma Sa |
THIENO(2,3-c)PYRAZOLES SUBSTITUES, PROCEDE DE PREPARATION, COMPOSITIONS LES CONTENANT ET UTILISATION
|
US20060142247A1
(en)
*
|
2004-12-17 |
2006-06-29 |
Guy Georges |
Tricyclic heterocycles
|
MX2007008008A
(es)
|
2004-12-30 |
2007-11-12 |
Astex Therapeutics Ltd |
Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora.
|
US7622583B2
(en)
|
2005-01-14 |
2009-11-24 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
ES2552338T3
(es)
|
2005-01-21 |
2015-11-27 |
Astex Therapeutics Limited |
Compuestos farmacéuticos
|
AU2006207321B2
(en)
|
2005-01-21 |
2012-09-06 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
MX2007009017A
(es)
*
|
2005-01-26 |
2007-09-19 |
Schering Corp |
Derivados de 3-(indazol-5-il)-(1,2,4)triazina y compuestos relacionados como inhibidores de proteina cinasa para el tratamiento de cancer.
|
EP1847532B1
(en)
*
|
2005-01-27 |
2013-06-05 |
Kyowa Hakko Kirin Co., Ltd. |
Igf-1r inhibitor
|
US7538113B2
(en)
|
2005-02-18 |
2009-05-26 |
Wyeth |
4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7582634B2
(en)
|
2005-02-18 |
2009-09-01 |
Wyeth |
7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7534796B2
(en)
|
2005-02-18 |
2009-05-19 |
Wyeth |
Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
|
EP2465857B1
(en)
|
2005-05-17 |
2014-06-04 |
Novartis AG |
Methods for synthesizing heterocyclic compounds
|
US7531542B2
(en)
|
2005-05-18 |
2009-05-12 |
Wyeth |
Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
|
CA2608952A1
(en)
*
|
2005-05-19 |
2006-11-23 |
Dwayne Thomas Friesen |
Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
|
CN101228161B
(zh)
*
|
2005-05-20 |
2012-10-10 |
沃泰克斯药物股份有限公司 |
适用作蛋白激酶抑制剂的吡咯并吡啶类
|
US7582636B2
(en)
|
2005-05-26 |
2009-09-01 |
Wyeth |
Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
|
US7541367B2
(en)
|
2005-05-31 |
2009-06-02 |
Janssen Pharmaceutica, N.V. |
3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
|
US7888381B2
(en)
|
2005-06-14 |
2011-02-15 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
|
US9006240B2
(en)
|
2005-08-02 |
2015-04-14 |
Eisai R&D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
MY148529A
(en)
|
2005-11-29 |
2013-04-30 |
Novartis Ag |
Formulations of quinolinones
|
TW200732305A
(en)
*
|
2005-12-23 |
2007-09-01 |
Yung Shin Pharmaceutical Ind |
Cancer chemotherapy
|
EP1981851B1
(en)
|
2006-01-31 |
2012-01-25 |
Array Biopharma, Inc. |
Kinase inhibitors and methods of use thereof
|
CA2645892A1
(en)
*
|
2006-03-23 |
2007-09-27 |
F. Hoffmann-La Roche Ag |
Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
|
AU2007347115A1
(en)
|
2006-04-04 |
2008-10-23 |
The Regents Of The University Of California |
PI3 kinase antagonists
|
EP2036557B1
(en)
|
2006-05-18 |
2015-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
WO2008001885A1
(fr)
|
2006-06-30 |
2008-01-03 |
Kyowa Hakko Kirin Co., Ltd. |
INHIBITEUR DE KINASE Abl
|
CN101484426A
(zh)
|
2006-06-30 |
2009-07-15 |
协和发酵麒麟株式会社 |
Aurora抑制剂
|
US8519135B2
(en)
|
2006-07-14 |
2013-08-27 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2/CCR9
|
WO2008020606A1
(fr)
*
|
2006-08-16 |
2008-02-21 |
Kyowa Hakko Kirin Co., Ltd. |
Agent anti-angiogénique
|
CN101511793B
(zh)
*
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
针对未分化型胃癌的抗肿瘤剂
|
CL2007002617A1
(es)
|
2006-09-11 |
2008-05-16 |
Sanofi Aventis |
Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
|
EP2119707B1
(en)
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
TW200901975A
(en)
|
2007-03-05 |
2009-01-16 |
Kyowa Hakko Kogyo Kk |
Pharmaceutical composition
|
WO2008113255A1
(fr)
*
|
2007-03-16 |
2008-09-25 |
The Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla |
Dérivés de benzamide avec activité antiproliférative, leurs préparations pharmaceutiques
|
CN103626739B
(zh)
*
|
2007-04-05 |
2015-12-30 |
辉瑞产品公司 |
适用于治疗哺乳动物异常细胞生长的6-[2-(甲基-氨甲酰基)苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型
|
DE602008003055D1
(de)
|
2007-05-31 |
2010-12-02 |
Nerviano Medical Sciences Srl |
Zyklokondensierte Azaindole, die als Kinase-Hemmer wirken
|
US7884110B2
(en)
|
2007-07-12 |
2011-02-08 |
Chemocentryx, Inc. |
Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
|
WO2009046448A1
(en)
|
2007-10-04 |
2009-04-09 |
Intellikine, Inc. |
Chemical entities and therapeutic uses thereof
|
AU2008310663A1
(en)
*
|
2007-10-11 |
2009-04-16 |
Vertex Pharmaceuticals Incorporated |
Aryl amides useful as inhibitors of voltage-gated sodium channels
|
JP5444239B2
(ja)
|
2007-11-02 |
2014-03-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
タンパク質キナーゼC−θとしての[1H−ピラゾロ[3,4−B]ピリジン−4−イル]−フェニレンまたは−ピリジン−2−イル誘導体
|
EP2218712B1
(en)
|
2007-11-09 |
2015-07-01 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
EP2240452B1
(en)
|
2008-01-04 |
2019-05-29 |
Intellikine, LLC |
1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as pi3 kinase modulators, their compositions and uses
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤および使用方法
|
CN104710365A
(zh)
|
2008-04-28 |
2015-06-17 |
旭化成制药株式会社 |
苯丙酸衍生物及其用途
|
CA2730106A1
(en)
|
2008-07-08 |
2010-01-14 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
US8772326B2
(en)
|
2008-07-10 |
2014-07-08 |
Anigion Biomedica Corp. |
Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
|
JP5731978B2
(ja)
|
2008-09-26 |
2015-06-10 |
インテリカイン, エルエルシー |
複素環キナーゼ阻害剤
|
AU2009305669A1
(en)
|
2008-10-16 |
2010-04-22 |
The Regents Of The University Of California |
Fused ring heteroaryl kinase inhibitors
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
SG10201401169QA
(en)
|
2009-04-02 |
2014-05-29 |
Merck Serono Sa |
Dihydroorotate dehydrogenase inhibitors
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン, エルエルシー |
複素環式化合物およびその使用
|
CN102595900B
(zh)
|
2009-08-10 |
2015-07-15 |
萨穆梅德有限公司 |
Wnt信号传导途径的吲唑抑制剂及其治疗用途
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
WO2011073521A1
(en)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Methods for enriching adult-derived endothelial progenitor cells and uses thereof
|
PL3001903T3
(pl)
|
2009-12-21 |
2018-03-30 |
Samumed, Llc |
1H-pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne
|
WO2011090738A2
(en)
|
2009-12-29 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
UY33236A
(es)
|
2010-02-25 |
2011-09-30 |
Novartis Ag |
Inhibidores dimericos de las iap
|
EA201290919A1
(ru)
*
|
2010-03-16 |
2013-03-29 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Индазольные соединения и их применение
|
AU2011255218B2
(en)
|
2010-05-21 |
2015-03-12 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
AU2011270165B2
(en)
|
2010-06-25 |
2015-12-24 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
EP2596026B1
(en)
|
2010-07-23 |
2020-04-08 |
Trustees of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
EP2651917A1
(en)
|
2010-12-13 |
2013-10-23 |
Novartis AG |
Dimeric iap inhibitors
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
NZ612909A
(en)
|
2011-01-10 |
2015-09-25 |
Infinity Pharmaceuticals Inc |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
CN106619647A
(zh)
|
2011-02-23 |
2017-05-10 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
JP2014509660A
(ja)
|
2011-04-01 |
2014-04-21 |
ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション |
PDK1キナーゼの阻害剤としての置換3−(1H−ベンゾ{d}イミダゾール−2−イル)−1H−インダゾール類似体
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
MX2014000648A
(es)
|
2011-07-19 |
2014-09-25 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y sus usos.
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
US8575336B2
(en)
*
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
AR091790A1
(es)
|
2011-08-29 |
2015-03-04 |
Infinity Pharmaceuticals Inc |
Derivados de isoquinolin-1-ona y sus usos
|
WO2013077921A2
(en)
|
2011-09-02 |
2013-05-30 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
CN102432595B
(zh)
*
|
2011-09-14 |
2013-09-25 |
湖南有色凯铂生物药业有限公司 |
N-吲哚-1-酰胺类化合物及作为抗癌药物的应用
|
IN2014CN02646A
(US07585860-20090908-C00154.png)
|
2011-09-14 |
2015-08-07 |
Samumed Llc |
|
CA2849995A1
(en)
|
2011-09-27 |
2013-04-04 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
JP6106685B2
(ja)
|
2011-11-17 |
2017-04-05 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
C−jun−n−末端キナーゼ(jnk)の阻害剤
|
EP2788330A1
(en)
|
2011-12-05 |
2014-10-15 |
Novartis AG |
Cyclic urea derivatives as androgen receptor antagonists
|
FR2985257B1
(fr)
*
|
2011-12-28 |
2014-02-14 |
Sanofi Sa |
Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
|
JP6158833B2
(ja)
|
2012-01-09 |
2017-07-05 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
ベータ−カテニン関連疾患を処置するための有機組成物
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CN104271133B
(zh)
|
2012-05-04 |
2017-10-13 |
萨穆梅德有限公司 |
1H‑吡唑并[3,4‑b]吡啶及其治疗应用
|
ES2618003T3
(es)
|
2012-06-13 |
2017-06-20 |
Incyte Holdings Corporation |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
JP6231262B2
(ja)
*
|
2012-06-20 |
2017-11-15 |
大日本印刷株式会社 |
ピタバスタチンカルシウムの前駆体の製造法
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
JP2015532287A
(ja)
|
2012-09-26 |
2015-11-09 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ire1の調節
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
CN103804349A
(zh)
*
|
2012-11-01 |
2014-05-21 |
杨子娇 |
一类治疗青光眼的化合物及其用途
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
MX370487B
(es)
|
2013-01-08 |
2019-12-16 |
Samumed Llc |
Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos.
|
CN104370889A
(zh)
*
|
2013-01-24 |
2015-02-25 |
韩冰 |
一类降低眼压的化合物及其制备方法和用途
|
KR101791762B1
(ko)
*
|
2013-02-02 |
2017-11-20 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
치환된 2-아미노피리딘 단백질 키나제 억제제
|
ES2671516T3
(es)
|
2013-02-19 |
2018-06-06 |
Novartis Ag |
Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
|
EA028033B1
(ru)
|
2013-03-14 |
2017-09-29 |
Новартис Аг |
3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантного idh
|
CN105209460A
(zh)
|
2013-03-14 |
2015-12-30 |
诺华股份有限公司 |
作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014147586A1
(en)
|
2013-03-22 |
2014-09-25 |
Novartis Ag |
1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
|
US9533984B2
(en)
|
2013-04-19 |
2017-01-03 |
Incyte Holdings Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
MX368099B
(es)
|
2013-05-14 |
2019-09-19 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
|
US20150018376A1
(en)
*
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
CN103387565B
(zh)
*
|
2013-07-29 |
2014-10-29 |
苏州明锐医药科技有限公司 |
阿西替尼的制备方法
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
SG10201902074UA
(en)
|
2013-10-04 |
2019-04-29 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
US10047070B2
(en)
|
2013-10-18 |
2018-08-14 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CN103570696B
(zh)
*
|
2013-11-06 |
2016-02-24 |
湖南欧亚生物有限公司 |
一种阿西替尼中间体的制备方法以及在制备阿西替尼中的应用
|
WO2015067224A1
(en)
|
2013-11-08 |
2015-05-14 |
Zentiva, K.S. |
Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
ES2699351T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
|
US9815813B2
(en)
|
2014-01-17 |
2017-11-14 |
Novartis Ag |
1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
CA2943075C
(en)
|
2014-03-19 |
2023-02-28 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
WO2015152117A1
(ja)
*
|
2014-03-31 |
2015-10-08 |
千寿製薬株式会社 |
アルキニルインダゾール誘導体及びその用途
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
JP2017516779A
(ja)
|
2014-05-28 |
2017-06-22 |
アイデニクス・ファーマシューティカルズ・エルエルシー |
癌治療のためのヌクレオシド誘導体
|
CN104072484B
(zh)
*
|
2014-07-07 |
2016-07-06 |
渤海大学 |
氮-(4-(芳巯基)-1氢-吲唑-3-基)-1-(芳杂环取代)甲基亚胺类化合物及其药学上可接受的盐及其制备方法和应用
|
AR101196A1
(es)
|
2014-07-16 |
2016-11-30 |
Gruenenthal Gmbh |
Compuestos de pirimidina sustituidos
|
AR101198A1
(es)
|
2014-07-16 |
2016-11-30 |
Gruenenthal Gmbh |
Pirimidinas 2,5-sustituidas como inhibidores de pde4b
|
PT3524595T
(pt)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040188A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040182A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
CN107001330A
(zh)
|
2014-09-17 |
2017-08-01 |
赛尔基因昆蒂赛尔研究公司 |
组蛋白脱甲基酶抑制剂
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
US10508108B2
(en)
|
2014-12-05 |
2019-12-17 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant IDH enzymes
|
WO2016089797A1
(en)
|
2014-12-05 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
WO2016089833A1
(en)
|
2014-12-05 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
MA41140A
(fr)
|
2014-12-12 |
2017-10-17 |
Cancer Research Tech Ltd |
Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
|
MA41179A
(fr)
*
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
EP3236959A4
(en)
|
2014-12-23 |
2018-04-25 |
Dana Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US20180000771A1
(en)
|
2015-01-13 |
2018-01-04 |
Kyoto University |
Agent for preventing and/or treating amyotrophic lateral sclerosis
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
EP3617205B1
(en)
|
2015-02-20 |
2021-08-04 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
SI3263106T1
(sl)
|
2015-02-25 |
2024-02-29 |
Eisai R&D Management Co., Ltd. |
Postopek zatiranja grenkobe derivata kinolina
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
US9580406B2
(en)
|
2015-04-28 |
2017-02-28 |
Signa S.A. De C.V. |
Processes for the preparation of axitinib
|
EP3303361A1
(en)
|
2015-05-27 |
2018-04-11 |
Idenix Pharmaceuticals LLC |
Nucleotides for the treatment of cancer
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
WO2016203404A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
US10308660B2
(en)
|
2015-06-19 |
2019-06-04 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
CN107922388B
(zh)
|
2015-06-19 |
2020-12-29 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
GB201511382D0
(en)
|
2015-06-29 |
2015-08-12 |
Imp Innovations Ltd |
Novel compounds and their use in therapy
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
US10285982B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10188634B2
(en)
|
2015-08-03 |
2019-01-29 |
Samumed, Llc |
3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023993A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017024003A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10195185B2
(en)
|
2015-08-03 |
2019-02-05 |
Samumed, Llc |
3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023986A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
|
US10166218B2
(en)
|
2015-08-03 |
2019-01-01 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10285983B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
|
WO2017024025A1
(en)
|
2015-08-03 |
2017-02-09 |
Sunil Kumar Kc |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10392383B2
(en)
|
2015-08-03 |
2019-08-27 |
Samumed, Llc |
3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10206909B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017024010A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
WO2017024021A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
WO2017023984A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
WO2017023975A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
US10226448B2
(en)
|
2015-08-03 |
2019-03-12 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
|
US10329309B2
(en)
|
2015-08-03 |
2019-06-25 |
Samumed, Llc |
3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
BR112018002757A8
(pt)
|
2015-08-13 |
2023-04-11 |
Merck Sharp & Dohme |
Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir uma produção de interferon tipo i e para tratamento de um distúrbio
|
JP7028766B2
(ja)
|
2015-09-09 |
2022-03-02 |
ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
US10160761B2
(en)
|
2015-09-14 |
2018-12-25 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
|
CN108367165B
(zh)
*
|
2015-10-07 |
2022-03-04 |
艾葳生物科技有限公司 |
治疗皮肤纤维化病症的组合物和方法
|
CA3002875A1
(en)
*
|
2015-10-22 |
2017-04-27 |
Selvita S.A. |
Pyridone derivatives and their use as kinase inhibitors
|
WO2017079759A1
(en)
|
2015-11-06 |
2017-05-11 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
|
EP3389783B1
(en)
|
2015-12-15 |
2024-07-03 |
Merck Sharp & Dohme LLC |
Novel compounds as indoleamine 2,3-dioxygenase inhibitors
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
SI3452465T1
(sl)
|
2016-05-04 |
2021-04-30 |
Genoscience Pharma |
Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni
|
CN109476660B
(zh)
|
2016-06-01 |
2023-04-04 |
拜斯丽治疗有限公司 |
N-(5-(3-(7-(3-氟苯基)-3h-咪唑并[4,5-c]吡啶-2-基)-1h-吲唑-5-基)吡啶-3-基)-3-甲基丁酰胺的制备方法
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
PT3468972T
(pt)
|
2016-06-14 |
2020-08-21 |
Novartis Ag |
Compostos e composições para inibir a atividade da shp2
|
SG11201811237WA
(en)
|
2016-06-24 |
2019-01-30 |
Infinity Pharmaceuticals Inc |
Combination therapies
|
MY196383A
(en)
|
2016-10-04 |
2023-03-28 |
Merck Sharp & Dohme Llc |
Benzo[B]Thiophene Compounds As Sting Agonists
|
CN110709082A
(zh)
|
2016-10-21 |
2020-01-17 |
萨穆梅德有限公司 |
吲唑-3-甲酰胺的使用方法及其作为Wnt/β-连环蛋白信号传导途径抑制剂的用途
|
WO2018085865A1
(en)
|
2016-11-07 |
2018-05-11 |
Samumed, Llc |
Single-dose, ready-to-use injectable formulations
|
WO2018091542A1
(en)
|
2016-11-21 |
2018-05-24 |
Idenix Pharmaceuticals Llc |
Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
|
MX2019005810A
(es)
|
2016-11-23 |
2019-09-11 |
Chemocentryx Inc |
Método para tratar glomeruloesclerosis segmentaria focal.
|
ES2891326T3
(es)
|
2017-01-27 |
2022-01-27 |
Janssen Biotech Inc |
Dinucleótidos cíclicos como agonistas de la STING
|
WO2018138685A2
(en)
|
2017-01-27 |
2018-08-02 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
JP6803410B2
(ja)
*
|
2017-02-14 |
2020-12-23 |
富士フイルム株式会社 |
インダゾール化合物の製造方法およびインダゾール化合物
|
US11466047B2
(en)
|
2017-05-12 |
2022-10-11 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
CN108947970B
(zh)
*
|
2017-05-18 |
2022-04-05 |
四川大学 |
吲唑类衍生物及其制备方法和用途
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
JP2020530838A
(ja)
|
2017-08-04 |
2020-10-29 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
がん治療のためのベンゾ[b]チオフェンSTINGアゴニスト
|
US11312772B2
(en)
|
2017-08-04 |
2022-04-26 |
Merck Sharp & Dohme Corp. |
Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment
|
SG11202000940XA
(en)
|
2017-08-24 |
2020-02-27 |
Novo Nordisk As |
Glp-1 compositions and uses thereof
|
US10435389B2
(en)
|
2017-09-11 |
2019-10-08 |
Krouzon Pharmaccuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
|
US11052065B2
(en)
|
2017-09-27 |
2021-07-06 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist
|
EP3694504A4
(en)
|
2017-10-11 |
2021-07-14 |
ChemoCentryx, Inc. |
TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CRC2 ANTAGONISTS
|
US20210179607A1
(en)
|
2017-11-01 |
2021-06-17 |
Merck Sharp & Dohme Corp. |
Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
ES2948307T3
(es)
|
2017-11-14 |
2023-09-08 |
Merck Sharp & Dohme Llc |
Nuevos compuestos de biarilo sustituidos como inhibidores de indolamina 2,3-dioxigenasa (IDO)
|
US11498904B2
(en)
|
2017-11-14 |
2022-11-15 |
Merck Sharp & Dohme Llc |
Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
|
US11685761B2
(en)
|
2017-12-20 |
2023-06-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
EP3774765A4
(en)
|
2018-04-03 |
2021-12-29 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|
MX2020010407A
(es)
|
2018-04-03 |
2020-10-22 |
Merck Sharp & Dohme |
Benzotiofenos y compuestos relacionados como agonistas de sting.
|
BR112020022373A2
(pt)
|
2018-05-04 |
2021-02-02 |
Incyte Corporation |
sais de um inibidor de fgfr
|
SG11202010636VA
(en)
|
2018-05-04 |
2020-11-27 |
Incyte Corp |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
CN110452176A
(zh)
*
|
2018-05-07 |
2019-11-15 |
四川大学 |
吲唑类衍生物及其制备方法和用途
|
US11352320B2
(en)
|
2018-05-31 |
2022-06-07 |
Merck Sharp & Dohme Corp. |
Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
|
CR20210175A
(es)
|
2018-09-18 |
2021-06-01 |
Nikang Therapeutics Inc |
Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2)
|
JP2022502495A
(ja)
|
2018-09-25 |
2022-01-11 |
ブラック ダイアモンド セラピューティクス,インコーポレイティド |
チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用
|
WO2020068873A1
(en)
|
2018-09-25 |
2020-04-02 |
Black Diamond Therapeutics, Inc. |
Tyrosine kinase inhibitor compositions, methods of making and methods of use
|
CN112839715A
(zh)
|
2018-09-29 |
2021-05-25 |
诺华股份有限公司 |
抑制shp2活性化合物的制造方法
|
US20210395240A1
(en)
|
2018-11-01 |
2021-12-23 |
Merck Sharp & Dohme Corp. |
Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
EP3877366A4
(en)
|
2018-11-06 |
2022-08-24 |
Merck Sharp & Dohme Corp. |
NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS
|
CN111205227A
(zh)
*
|
2018-11-22 |
2020-05-29 |
四川大学 |
3-乙烯基吲唑类衍生物及其制备方法和用途
|
EP3886845A4
(en)
|
2018-11-28 |
2022-08-10 |
Merck Sharp & Dohme Corp. |
NEW SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS USED AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
|
JP7532385B2
(ja)
*
|
2019-01-31 |
2024-08-13 |
杏林製薬株式会社 |
15-pgdh阻害薬
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
EP3946324A4
(en)
|
2019-04-04 |
2022-11-30 |
Merck Sharp & Dohme LLC |
HISTONE DEACETYLASE-3 INHIBITORS USEFUL FOR THE TREATMENT OF CANCER, INFLAMMATION, NEURODEGENERATIVE DISEASES AND DIABETES
|
SG11202110406SA
(en)
|
2019-04-11 |
2021-10-28 |
Angion Biomedica Corp |
Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole
|
EA202192731A1
(ru)
|
2019-04-18 |
2022-02-04 |
Синтон Б.В. |
СПОСОБ ПОЛУЧЕНИЯ АКСИТИНИБА, СПОСОБ ОЧИСТКИ ПРОМЕЖУТОЧНОГО СОЕДИНЕНИЯ 2-((3-ЙОД-1H-ИНДАЗОЛ-6-ИЛ)ТИО)-N-МЕТИЛБЕНЗАМИДА, СПОСОБ ОЧИСТКИ АКСИТИНИБА ЧЕРЕЗ HCl СОЛЬ АКСИТИНИБА, ТВЕРДАЯ ФОРМА HCl СОЛИ АКСИТИНИБА
|
WO2020225413A1
(en)
|
2019-05-09 |
2020-11-12 |
Synthon B.V. |
Pharmaceutical composition comprising axitinib
|
EP3990635A1
(en)
|
2019-06-27 |
2022-05-04 |
Rigontec GmbH |
Design method for optimized rig-i ligands
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
TW202120500A
(zh)
|
2019-08-02 |
2021-06-01 |
美商梅爾莎納醫療公司 |
干擾素基因刺激蛋白(sting)激動劑化合物及用途
|
JP2022544656A
(ja)
|
2019-08-15 |
2022-10-20 |
ブラック ダイアモンド セラピューティクス,インコーポレイティド |
アルキニルキナゾリン化合物
|
AU2020338490A1
(en)
*
|
2019-08-30 |
2022-03-17 |
Risen (Suzhou) Pharma Tech Co., Ltd. |
Prodrugs of the tyrosine kinase inhibitor for treating cancer
|
CN112442010B
(zh)
*
|
2019-08-30 |
2023-10-03 |
润佳(苏州)医药科技有限公司 |
一类前药化合物及其在治疗癌症方面的应用
|
CN112442011B
(zh)
*
|
2019-08-30 |
2023-11-14 |
润佳(苏州)医药科技有限公司 |
一种前药化合物及其在治疗癌症方面的应用
|
BR112022007163A2
(pt)
|
2019-10-14 |
2022-08-23 |
Incyte Corp |
Heterociclos bicíclicos como inibidores de fgfr
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
CN112694474B
(zh)
*
|
2019-10-23 |
2022-03-18 |
四川大学 |
吲唑类衍生物及其制备方法和用途
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
PE20221504A1
(es)
|
2019-12-04 |
2022-09-30 |
Incyte Corp |
Derivados de un inhibidor de fgfr
|
US20230074558A1
(en)
|
2019-12-06 |
2023-03-09 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
CN111829859B
(zh)
*
|
2020-01-20 |
2024-01-05 |
北京林业大学 |
一种高效杨树种子透明染色及其三维成像的方法
|
CA3165359A1
(en)
|
2020-02-18 |
2021-07-22 |
Dorthe Kot Engelund |
Glp-1 compositions and uses thereof
|
BR102020005423A2
(pt)
*
|
2020-03-18 |
2021-09-28 |
Faculdades Catolicas |
Compostos n-acil-hidrazônicos, uso no tratamento de agregopatias degenerativas amiloides e não-amiloides, e composição farmacêutica
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
EP4146644A1
(en)
|
2020-05-06 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Il4i1 inhibitors and methods of use
|
WO2021232367A1
(zh)
*
|
2020-05-21 |
2021-11-25 |
四川大学 |
3-乙烯基吲唑类衍生物及其制备方法和用途
|
CN113943271B
(zh)
*
|
2020-07-15 |
2023-11-14 |
鲁南制药集团股份有限公司 |
一种阿昔替尼晶型及其制备方法
|
CN112028831A
(zh)
*
|
2020-09-24 |
2020-12-04 |
山东大学 |
一种苯并吡唑类化合物、其制备方法及作为抗肿瘤药物的应用
|
CA3202355A1
(en)
|
2020-12-22 |
2022-06-30 |
Jiping Fu |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
AU2022207648A1
(en)
|
2021-01-13 |
2023-07-27 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
JP2024513575A
(ja)
|
2021-04-12 |
2024-03-26 |
インサイト・コーポレイション |
Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
|
WO2022219407A1
(en)
|
2021-04-14 |
2022-10-20 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
WO2022219412A1
(en)
|
2021-04-14 |
2022-10-20 |
Monte Rosa Therapeutics Ag |
Isoindolinone amide compounds useful to treat diseases associated with gspt1
|
WO2022227015A1
(en)
|
2021-04-30 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Il4i1 inhibitors and methods of use
|
JP2024522189A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Fgfr阻害剤としての三環式ヘテロ環
|
EP4370522A1
(en)
|
2021-07-14 |
2024-05-22 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
CN115701423A
(zh)
*
|
2021-08-02 |
2023-02-10 |
沈阳化工大学 |
三氟乙基硫醚(亚砜)取代苯类化合物的制备方法及其中间体
|
WO2023192801A1
(en)
|
2022-03-28 |
2023-10-05 |
Nikang Therapeutics, Inc. |
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
|
EP4282415A1
(en)
|
2022-05-26 |
2023-11-29 |
Genepharm S.A. |
A stable tablet composition of axitinib
|
WO2023240024A1
(en)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2024032584A1
(zh)
*
|
2022-08-08 |
2024-02-15 |
苏州必扬医药科技有限公司 |
一种蛋白酪氨酸激酶抑制剂及其医疗用途
|
WO2024102849A1
(en)
|
2022-11-11 |
2024-05-16 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|